Trial · NCT07904390
Hop Extract Versus Soy Isoflavone Extract for Menopausal Symptoms (HOPES)
NCT07904390, Not applicable, Recruiting, Menoclinica by Palacios
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hop Extract Versus Soy Isoflavone Extract for Menopausal Symptoms (HOPES). Trials, record NCT07904390. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904390
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hop Extract Versus Soy Isoflavone Extract for Menopausal Symptoms (HOPES)
- NCT number
- NCT07904390
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Menoclinica by Palacios
- Conditions
- Menopause, Perimenopause, Postmenopause
- Interventions
- Full Spectrum hop extract (MENODUO FullSpectrum), Soy isoflavone extract
- First posted
- 2026-10-29
- Last updated
- 2026-11-05
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in the psychological subscale score of the Menopause Rating Scale (MRS) | Baseline (visit 1) and week 12 (visit 3) | The MRS psychological subscale is the sum of items 4 to 7 (depressive mood, irritability, anxiety, and physical and mental exhaustion), each rated from 0 (none) to 4 (very severe). Score range 0 to 16; higher scores indicate greater symptom severity. Change is the week 12 score minus the baseline score. |
| Secondary | Change in total MRS score | Baseline, week 6 and week 12 | Sum of the 11 MRS items, each rated 0 to 4. Score range 0 to 44; higher scores indicate greater severity. |
| Secondary | Change in MRS somatic-vegetative subscale score | Baseline, week 6 and week 12 | Sum of items 1, 2, 3 and 11. Score range 0 to 16; higher scores indicate greater severity. |
| Secondary | Change in MRS urogenital subscale score | Baseline, week 6 and week 12 | Sum of items 8, 9 and 10. Score range 0 to 12; higher scores indicate greater severity. |
| Secondary | Change in Generalized Anxiety Disorder-7 (GAD-7) score | Baseline and week 12 (optional at week 6) | Seven items rated 0 to 3. Score range 0 to 21; higher scores indicate more anxiety symptoms. |
| Secondary | Change in Patient Health Questionnaire-9 (PHQ-9) score | Baseline and week 12 (optional at week 6) | Nine items rated 0 to 3. Score range 0 to 27; higher scores indicate more depressive symptoms. |
| Secondary | Change in the Cervantes Scale global score | Baseline and week 12 | The Cervantes Scale is a 31-item, menopause-specific health-related quality of life questionnaire. Each item is rated from 0 to 5. The global score ranges from 0 to 155; higher scores indicate worse health-related quality of life. Change is the week 12 score minus the baseline score. |
| Secondary | Change in the Cervantes Scale sexuality domain score | Baseline and week 12 | The sexuality domain of the Cervantes Scale (31-item, menopause-specific health-related quality of life questionnaire) comprises 4 items on sexual function, each rated from 0 to 5. The domain score ranges from 0 to 20; higher scores indicate worse sexual function. Change is the week 12 score minus the baseline score. |
| Secondary | Change in body fat percentage | Baseline and week 12 | Body fat percentage measured by bioimpedance. |
| Secondary | Change in estimated visceral fat | Baseline and week 12 | Visceral fat estimate measured by bioimpedance. |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904390
GET https://conductscience.org/api/trials/v1/NCT07904390/registered